Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China
By Bo Li, Jing Yang, Faming Zhao, L. Zhi, Xiqian Wang, Lin Liu, Zhaohui Bi, Yunhe Zhao. Clinical Research in Cardiology, 2020
1,794 citations recorded by the source corpus.
Background Studies have reminded that cardiovascular metabolic comorbidities made patients more susceptible to suffer 2019 novel corona virus (2019-nCoV) disease (COVID-19), and exacerbated the infection. The aim of this analysis is to determine the association of cardiovascular metabolic diseases with the development of COVID-19. Methods A meta-analysis of eligible studies that summarized the prevalence of cardiovascular metabolic diseases in COVID-19 and compared the incidences of the comorbidities in ICU/severe and non-ICU/severe patients was performed. Embase and PubMed were searched for relevant studies. Results A total of six studies with 1527 patients were included in this analysis. The proportions of hypertension, cardia-cerebrovascular disease and diabetes in patients with COVID-19 were 17.1%, 16.4% and 9.7%, respectively. The incidences of hypertension, cardia-cerebrovascular diseases and diabetes were about twofolds, threefolds and twofolds, respectively, higher in ICU/severe cases than in their non-ICU/severe counterparts. At least 8.0% patients with COVID-19 suffered the acute cardiac injury. The incidence of acute cardiac injury was about 13 folds higher in ICU/severe patients compared with the non-ICU/severe patients. Conclusion Patients with previous cardiovascular metabolic diseases may face a greater risk of developing into the severe condition and the comorbidities can also greatly affect the prognosis of the COVID-19. On the other hand, COVID-19 can, in turn, aggravate the damage to the heart.
Subfields: Cardiology and Cardiovascular Medicine, Infectious Diseases, Neurology
View Paper: https://www.semanticscholar.org/paper/53ea977693c5f66cc9c66dd5bd1674966ec17db4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Neurology
Citations in the corpus
- COVID-19 and diabetes: Knowledge in progress (2020, neutral): “[28] Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al.”
- Comorbidity and its Impact on Patients with COVID-19 (2020, background): “Once again, insufficient sample size and inadequate time have led to limitations in the data collected [32].”
- Cardiovascular disease and COVID-19 (2020, background): “Following are the common mechanisms responsible for CV complications in COVID-19 [3,4]-”
- Cardiovascular complications in COVID-19 (2020, neutral): “A meta-analysis of 1527 patients with COVID-19 found that the prevalence of hypertension was 17.1% and cardiac disease was 16.4%, and that these patients were more likely to require critical care [18] .”